---
title: Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents
nct_id: NCT02075203
overall_status: COMPLETED
phase: PHASE2
sponsor: Aeras
study_type: INTERVENTIONAL
primary_condition: Tuberculosis
countries: South Africa
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02075203.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02075203"
ct_last_update_post_date: 2019-09-04
last_seen_at: "2026-05-12T06:16:20.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

**Official Title:** A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents

**NCT ID:** [NCT02075203](https://clinicaltrials.gov/study/NCT02075203)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 989
- **Lead Sponsor:** Aeras
- **Collaborators:** Sanofi Pasteur, a Sanofi Company
- **Conditions:** Tuberculosis
- **Start Date:** 2014-02
- **Completion Date:** 2017-10-06
- **CT.gov Last Update:** 2019-09-04

## Brief Summary

Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection with Mycobacterium tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents

## Detailed Description

This Phase II, randomized, 3-arm, placebo controlled, partially blinded, clinical trial will be conducted in 990 healthy, HIV-uninfected, QFT-GIT negative, previously BCG vaccinated adolescents. The trial will be conducted at the South African Tuberculosis Vaccine Initiative (SATVI) site in the Western Cape region of South Africa, where epidemiological studies involving thousands of adolescents have been conducted over the last decade to characterize rates of Mtb infection and active TB disease in this age group. Subjects will be enrolled in two sequential cohorts and within each cohort subjects will be randomized in a 1:1:1 ratio to receive either AERAS-404 or saline placebo on Days 0 and 56, or BCG Vaccine SSI on Day 0. The first 90 subjects (30 from each arm) will form the Safety \& Immunogenicity Cohort and will be subject to more intensive collection of safety data, with data reviewed by the Data Monitoring Committee (DMC), principal investigator and local medical monitor. Selected immunogenicity assays, including whole blood intracellular cytokine staining (ICS), will also be performed in this cohort. The remaining 900 subjects will be enrolled into the Correlates Cohort. All 990 subjects in the study will be evaluated for safety and biomarker outcomes, and for prevention of Mtb infection.

The primary Mtb infection endpoint will be QFT-GIT conversion from a negative to positive test, using the manufacturer's recommended threshold of 0.35 IU/mL, at any time-point after Day 84 and through end of follow-up for the primary endpoint. The 84-day 'wash-out' period is stipulated in order to exclude subjects who may have already been Mtb infected, but not yet converted their QFT-GIT test at screening, thus subjects who convert their QFT-GIT at Day 84 will not be included in the analyses of prevention of Mtb infection.

## Eligibility

- **Minimum age:** 12 Years
- **Maximum age:** 17 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Has completed the written informed consent and assent process
2. Is age ≥ 12 years and ≤ 17 years on Study Day 0
3. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information
4. For female subjects: agrees to avoid pregnancy from 28 days prior to Study Day 0 and for the full duration of the study.
5. Has general good health, confirmed by medical history and physical examination
6. Had BCG vaccination at least 5 years ago documented through medical history or by presence of healed BCG scar
7. Tests QFT-GIT negative at screening, using the manufacturer's recommended threshold of 0.35 IU/mL

Exclusion Criteria:

1. Acute illness on Study Day 0
2. Oral temperature ≥37.5°C on Study Day 0
3. Clinically significant (and no more than Grade 1 on the Toxicity Scale) abnormal laboratory values from blood collected within 21 days
4. Evidence of clinically significant (and no more than Grade 1 on the Toxicity Scale) systemic or local disease on urinalysis
5. History or evidence of any clinically significant systemic disease, or any acute or chronic illness that might affect the safety, immunogenicity, or efficacy of study vaccine in the opinion of the investigator
6. History of treatment for active TB disease or latent Mtb infection
7. History or evidence, including chest X-ray, of active TB disease
8. Shared residence with an individual receiving anti-TB treatment, or known incompletely treated culture or smear positive TB
9. History of autoimmune disease or immunosuppression
10. Used immunosuppressive medication within 42 days before Study Day 0
11. Received immunoglobulin or blood products within 42 days before Study Day 0
12. Received any investigational drug therapy or investigational vaccine within 182 days before Study Day 0
13. Received investigational TB vaccine, other than BCG
14. Planned administration/administration of a licensed vaccine in the period starting 28 days before and ending 28 days after each dose of study vaccine
15. History or laboratory evidence of any past or present possible immunodeficiency state not limited to any lab indication of HIV-1 infection
16. History of allergic disease likely to be exacerbated by any component of the study vaccine
17. History of alcohol or drug abuse
18. All female subjects: currently pregnant or lactating/nursing; or positive urine pregnancy test during screening
19. Received a (TST) within 3 months (90 days) prior to Study Day 0.
20. Any current medical, psychiatric, occupational, substance abuse problems problems that in opinion of investigator will make unlikely for the subject to comply with the protocol
```

## Arms

- **AERAS-404 (15 mcgH4/500 nmol IC31)** (EXPERIMENTAL) — 2 doses on Study Days 0 and 56
- **Bacillus Calmette-Guérin (BCG)** (ACTIVE_COMPARATOR) — 1 Dose on Study Day 0
- **Placebo** (PLACEBO_COMPARATOR) — 2 Doses on Study Days 0 and 56

## Interventions

- **AERAS-404** (BIOLOGICAL) — The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK \& a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 \& saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
- **Placebo** (DRUG) — Saline
- **Bacillus Calmette-Guérin (BCG)** (BIOLOGICAL) — BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).

## Primary Outcomes

- **Safety Profile of H4:IC31 and BCG Revaccination in HIV-uninfected, Remotely BCG Vaccinated Adolescents.** _(time frame: Study day 7 thru 6 months after last vaccination)_ — Number of unsolicited and solicited adverse events recorded post vaccination.

Unsolicited adverse events: 28 days post each vaccination

Solicited adverse events: 7 days post each vaccination (with diary cards used for 7 days after each vaccination for Safety and Immunogenicity Cohort only)

Solicited and unsolicited injection site reaction adverse events: BCG Group - 84 days post vaccination; H4:IC31/Placebo Groups - 28 days post each vaccination

Serious adverse events, adverse events of special interest, and SUSARs: Entire study period, with a minimum of 6 months following the last dose of study vaccine
- **Number of Participants Testing Positive for Mtb at Day 84** _(time frame: Study day 84 through 6 months post-conversion)_ — Rates of conversion to Mtb-positive measured by QuantiFERON-TB Gold In-tube (QFT-GIT) assay. The primary evaluation of Mtb infection was QFT-GIT conversion from a negative to positive test, using the manufacturer's recommended threshold of ≥0.35 IU/mL, at any time point after Day 84 and through end of follow-up for the primary endpoint. All participants with primary QFT-GIT conversion were followed for an additional 6 months post-conversion to ascertain the sustained QFT-GIT conversion and QFT-GIT reversion endpoints. Participants with an initial QFT-GIT conversion at Month 6 or 12 were asked to return for a final QFT-GIT evaluation and assessment for TB signs and symptoms at least 24 months after their initial vaccination.

* H4:IC31 compared to placebo
* BCG revaccination compared to placebo

## Secondary Outcomes

- **Rates of Sustained Conversion to Mtb-positive** _(time frame: 6 months after initial conversion)_
- **Percentage of Participants With Immune Response to Vaccine in HIV-uninfected, Remotely BCG-vaccinated Adolescents: o H4:IC31 o BCG Revaccination** _(time frame: Study day 70)_

## Locations (2)

- South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester, Cape Town, Western Cape, South Africa
- Desmond Tutu HIV Foundation (DTHF), Nyanga, South Africa

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.south african tuberculosis vaccine initiative , project office, brewelskloof hospital , harlem street, worcester|cape town|western cape|south africa` — added _(2026-05-12)_
- `locations.desmond tutu hiv foundation (dthf)|nyanga||south africa` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02075203.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02075203*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*